Kinsale Capital Group, Inc. (KNSL) - Q1 2026 Filing Summary
Business Context and Reporting Period
This summary covers the Form 10-Q for Kinsale Capital Group, Inc., a specialty insurance company focused on the U.S. excess and surplus (E&S) lines market. The reporting period is the three months ended March 31, 2026. The company operates a single reportable segment offering commercial and personal lines property and casualty insurance.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Net Income | $112.6 million | $89.2 million | +26.1% |
| Earnings Per Share (Diluted) | $4.88 | $3.83 | +27.4% |
| Net Earned Premiums | $406.9 million | $365.8 million | +11.2% |
| Net Written Premiums | $403.3 million | $381.7 million | +5.6% |
| Combined Ratio | 77.4% | 82.1% | -4.7 pts |
| Loss Ratio | 56.3% | 62.1% | -5.8 pts |
| Expense Ratio | 21.1% | 20.0% | +1.1 pts |
| Net Investment Income | $55.4 million | $43.8 million | +26.5% |
| Total Assets | $6.22 billion | $6.04 billion | +2.8% |
| Stockholders' Equity | $1.97 billion | $1.58 billion | +24.7% |
| Debt (Total) | $224.5 million | $224.4 million | ~0% |
| Cash & Equivalents | $223.3 million | $142.0 million | +57.2% |
Material Changes vs. Prior Period
- Underwriting Performance: Underwriting income increased 40.1% to $94.5 million, driven by a 5.6% increase in net written premiums and significantly lower catastrophe losses ($1.6 million in Q1 2026 vs. $22.6 million in Q1 2025). Prior year loss reserves developed favorably by $18.7 million.
- Premium Mix: Gross written premiums declined slightly (0.5%) due to a 28.3% drop in the Commercial Property division caused by rate competition. However, net written premiums grew due to higher retention levels (83.7% vs. 78.8%).
- Investment Results: Net investment income rose 26.5% due to portfolio growth. However, the fair value of equity securities decreased by $8.4 million (vs. a gain of $3.0 million in Q1 2025), reducing total comprehensive income to $77.6 million.
- Capital Actions: The company repurchased 166,042 shares for $62.5 million and declared a quarterly dividend of $0.25 per share.
Outlook, Risks, and Contingencies
- Guidance: The filing contains forward-looking statements but does not provide specific numerical guidance for the full year 2026. Management notes that interim results are not necessarily indicative of full-year performance.
- Share Repurchase Program: As of March 31, 2026, $187.5 million of capacity remains under the $250 million program authorized in December 2025.
- Legal Contingency: A $140 million wrongful death verdict against a policyholder (Venetian Hills) was vacated by the Georgia Court of Appeals in October 2025, ordering a retrial. The company believes policy exclusions apply and does not expect a material adverse effect on financial results.
- Risk Factors: Key risks include inadequate loss reserves, severe weather/catastrophes, reinsurance availability, and interest rate volatility affecting the investment portfolio. The company maintains an "A" (Excellent) financial strength rating from A.M. Best.
Investor Verification Checklist
- Catastrophe Exposure: Verify the company's current probable maximum loss (PML) models and reinsurance coverage limits given the significant reduction in catastrophe losses compared to the prior year.
- Commercial Property Rates: Monitor the Commercial Property division's rate environment and submission flow, as this segment saw a 28% decline in gross written premiums.
- Investment Portfolio Duration: Review the weighted average duration of fixed-maturity securities (4.1 years) and sensitivity to interest rate changes, as unrealized losses on fixed-maturity securities increased to $106.3 million.
- Loss Reserve Development: Track the sustainability of the $18.7 million favorable prior-year development, noting the offsetting adverse development in construction liability lines.
- Debt Covenants: Confirm continued compliance with financial covenants under the Note Purchase Agreement and Credit Facility, particularly regarding restricted payments.